While software modeling is proving to be a valuable tool for assisting drug developers in streamlining drug development programmes, the accuracy of the simulations generated will always depend on the quality of the data applied to the model.
Here, Rob Harris, chief technical officer, and Matt Ling, technical director, Juniper Pharma Services (now a part of Catalent Pharma Solutions), explains why modeling can help to minimize the risks associated with the development of poorly soluble drugs.
This article highlights the scope for developing therapeutics with new innovative, alternative approaches. The current trillion dollars pharmaceutical industry is in peril where the current drug development pipeline is slow, inefficient and incapable of being extended to multi-combination drug therapies as well as minimally focused on prevention. The complex modeling of diseases and biological functions has been limited because of the inability to integrate large scale molecular pathways.
Watch this Video to understand how recent advances provide breakthrough technology for doing scalable modeling of complex molecular systems to dramatically accelerate drug discovery and development.